Evidence map›Paper›PMID 33686472›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2021

Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE.

João Pedro Ferreira, John G Cleland, Carolyn S P Lam, Stefan D Anker, Mandeep R Mehra, Dirk J van Veldhuisen, William M Byra, David A La Police, Bertram Pitt, Barry Greenberg and 1 more

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01877915 (A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01877915 phase3completednot on this map

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

TypeinterventionalSponsorJanssen Research & Development, LLCRan2013 to 2018Enrolled5,081ConditionsHeart Failure, Coronary Artery DiseaseArmsRivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. DNA Methylation Aberrant in Atherosclerosis.Frontiers in pharmacology · 2022
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

João Pedro FerreiraCentre d'investigations Cliniques Plurithématique, Inserm 1433, Université de Lorraine, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHRU Nancy-Hopitaux de Brabois, 4 rue du Morvan, 54500, Nancy, Vandoeuvre les Nancy, France. j.ferreira@chru-nancy.fr.ORCID http://orcid.org/0000-0002-2304-6138
John G ClelandRobertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, Scotland.
Carolyn S P LamNational Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore.
Stefan D AnkerBerlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.
Mandeep R MehraBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dirk J van VeldhuisenDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
William M ByraJanssen Research and Development, Raritan, NJ, USA.
David A La PoliceJanssen Research and Development, Raritan, NJ, USA.
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, USA.
Barry GreenbergCardiology Division, Department of Medicine, University of California, La Jolla, San Diego, USA.
Faiez ZannadCentre d'investigations Cliniques Plurithématique, Inserm 1433, Université de Lorraine, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHRU Nancy-Hopitaux de Brabois, 4 rue du Morvan, 54500, Nancy, Vandoeuvre les Nancy, France. f.zannad@chru-nancy.fr.
Inserm · FRJanssen (United States) · USUniversity Medical Center Groningen · NLBerlin-Brandenburger Centrum für Regenerative Therapien · DEBrigham and Women's Hospital · USUniversity of California San Diego · USUniversity of Glasgow · GBUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with coronary artery disease (CAD) are at increased risk of developing and being hospitalised for heart failure (HFH). However, the risk of HFH versus ischemic events may vary among patients with CAD, depending on whether acute myocardial infarction (MI), left ventricular dysfunction or decompensated HF is present at baseline.

aimsWe aim to explore the risk of non-fatal events (HFH, MI, stroke) and subsequent death in 3 landmark trials, COMMANDER-HF, EPHESUS and EXAMINE that, together, included patients with CAD with and without reduced ejection fraction and acute MI.

methodsEvents, person-time metrics and time-updated Cox models.

resultsIn COMMANDER-HF the event-rate for the composite of AMI, stroke or all-cause death was 13.5 (12.8-14.3) events/100 py. Rates for AMI and stroke were much lower (2.2 [2.0-2.6] and 1.3 [1.1-1.6] events/100 py, respectively) than the rate of HFH (16.9 [16.1-17.9] events/100 py). In EPHESUS, the rates of MI and stroke were also lower than the rate of HFH: 7.2 (6.7-7.8), 1.9 (1.7-2.3), and 10.6 (9.9-11.3) events/100 py, but this was not true for EXAMINE with 4.4 (4.0-4.9), 0.7 (0.6-0.9), and 2.4 (2.0-2.7) events/100 py, respectively. In all 3 trials, a non-fatal event (HFH, MI or stroke) during follow-up doubled the risk of subsequent mortality. This most commonly followed a HFH.

conclusionsA first or recurrent HFH is common in patients with CAD and AMI or HFrEF and indicates a poor prognosis. Preventing the development of heart failure after AMI and control of congestion in patients with CAD and HFrEF are key unmet needs and therapeutic targets. REGISTRATION: ClinicalTrials.gov Identifier: NCT01877915. URL: https://clinicaltrials.gov/ct2/show/NCT01877915 .

Indexed as

AgedCoronary Artery DiseaseFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedMyocardial InfarctionPatient ReadmissionPrognosisRandomized Controlled Trials as TopicStrokeVentricular Dysfunction, LeftEven-ratesEven typeHeart failureMyocardial infarctionStroke

Identifiers

PMID33686472
OpenAlexW3133677656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.